HER2疗法——选择众多。 - Suppr

Suppr

超能文献

HER2 therapy--an abundance of riches.

作者信息

Gradishar William J

出版信息

N Engl J Med. 2012 Jan 12;366(2):176-8. doi: 10.1056/NEJMe1113641. Epub 2011 Dec 7.

DOI:10.1056/NEJMe1113641

PMID:22149874

Abstract

摘要

相似文献

HER2 therapy--an abundance of riches.

N Engl J Med. 2012 Jan 12;366(2):176-8. doi: 10.1056/NEJMe1113641. Epub 2011 Dec 7.

Pertuzumab plus trastuzumab in metastatic breast cancer.

N Engl J Med. 2012 Apr 5;366(14):1348; author reply 1349-50. doi: 10.1056/NEJMc1201462.

Pertuzumab plus trastuzumab in metastatic breast cancer.

N Engl J Med. 2012 Apr 5;366(14):1348-9; author reply 1349-50. doi: 10.1056/NEJMc1201462.

Pertuzumab plus trastuzumab in metastatic breast cancer.

N Engl J Med. 2012 Apr 5;366(14):1349; author reply 1349-50. doi: 10.1056/NEJMc1201462.

Dual HER2 blockade slows metastatic breast cancer.

Cancer Discov. 2012 Jan;2(1):OF4. doi: 10.1158/2159-8290.CD-ND121511OL-12. Epub 2011 Dec 15.

Pertuzumab (Perjecta) for HER2-positive metastatic breast cancer.

Med Lett Drugs Ther. 2012 Jul 23;54(1395):59-60.

[Pertuzumab+trastuzumab+DTX therapy].

Nihon Rinsho. 2015 Feb;73 Suppl 2:553-7.

CLEOPATRA holds strong in final analysis.

Cancer Discov. 2014 Dec;4(12):OF3. doi: 10.1158/2159-8290.CD-NB2014-157. Epub 2014 Oct 16.

The clinical utility of HER2-targeted therapy in the neoadjuvant setting: recent results from the San Antonio Breast Cancer Symposium.

Clin Breast Cancer. 2011 Feb;11(1):15-9. doi: 10.3816/CBC.2011.n.003.

Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.

Expert Rev Anticancer Ther. 2015 Jan;15(1):17-26. doi: 10.1586/14737140.2015.992418. Epub 2014 Dec 12.

引用本文的文献

HER2; p53 Co-mutated Cancers Show Increased Histone Acetylation and are Sensitive to Neratinib plus Trastuzumab Deruxtecan.

bioRxiv. 2025 Jul 10:2025.07.06.663368. doi: 10.1101/2025.07.06.663368.

Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer-A Literature Review.

Cancers (Basel). 2023 Aug 30;15(17):4336. doi: 10.3390/cancers15174336.

Recent Advances in the Role of Autophagy in Endocrine-Dependent Tumors.

Endocr Rev. 2023 Jul 11;44(4):629-646. doi: 10.1210/endrev/bnad001.

Revisiting characteristics of oncogenic extrachromosomal DNA as mobile enhancers on neuroblastoma and glioma cancers.

Cancer Cell Int. 2022 May 25;22(1):200. doi: 10.1186/s12935-022-02617-8.

Lysine Acetylation/Deacetylation Modification of Immune-Related Molecules in Cancer Immunotherapy.

Front Immunol. 2022 May 2;13:865975. doi: 10.3389/fimmu.2022.865975. eCollection 2022.

Remodeling the Tumor Myeloid Landscape to Enhance Antitumor Antibody Immunotherapies.

Cancers (Basel). 2021 Sep 29;13(19):4904. doi: 10.3390/cancers13194904.

Laser Capture Proteomics: spatial tissue molecular profiling from the bench to personalized medicine.

Expert Rev Proteomics. 2021 Oct;18(10):845-861. doi: 10.1080/14789450.2021.1984886. Epub 2021 Dec 14.

Novel insights into extrachromosomal DNA: redefining the onco-drivers of tumor progression.

J Exp Clin Cancer Res. 2020 Oct 12;39(1):215. doi: 10.1186/s13046-020-01726-4.

Reprogramming the Constant Region of Immunoglobulin G Subclasses for Enhanced Therapeutic Potency against Cancer.

Biomolecules. 2020 Mar 1;10(3):382. doi: 10.3390/biom10030382.

Prevalence and role of HER2 mutations in cancer.

Pharmacol Ther. 2019 Jul;199:188-196. doi: 10.1016/j.pharmthera.2019.03.010. Epub 2019 Apr 2.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

HER2 therapy--an abundance of riches.

N Engl J Med. 2012 Jan 12;366(2):176-8. doi: 10.1056/NEJMe1113641. Epub 2011 Dec 7.

Pertuzumab plus trastuzumab in metastatic breast cancer.

N Engl J Med. 2012 Apr 5;366(14):1348; author reply 1349-50. doi: 10.1056/NEJMc1201462.

Pertuzumab plus trastuzumab in metastatic breast cancer.

N Engl J Med. 2012 Apr 5;366(14):1348-9; author reply 1349-50. doi: 10.1056/NEJMc1201462.

Pertuzumab plus trastuzumab in metastatic breast cancer.

N Engl J Med. 2012 Apr 5;366(14):1349; author reply 1349-50. doi: 10.1056/NEJMc1201462.

Dual HER2 blockade slows metastatic breast cancer.

Cancer Discov. 2012 Jan;2(1):OF4. doi: 10.1158/2159-8290.CD-ND121511OL-12. Epub 2011 Dec 15.

Pertuzumab (Perjecta) for HER2-positive metastatic breast cancer.

Med Lett Drugs Ther. 2012 Jul 23;54(1395):59-60.

[Pertuzumab+trastuzumab+DTX therapy].

Nihon Rinsho. 2015 Feb;73 Suppl 2:553-7.

CLEOPATRA holds strong in final analysis.

Cancer Discov. 2014 Dec;4(12):OF3. doi: 10.1158/2159-8290.CD-NB2014-157. Epub 2014 Oct 16.

The clinical utility of HER2-targeted therapy in the neoadjuvant setting: recent results from the San Antonio Breast Cancer Symposium.

Clin Breast Cancer. 2011 Feb;11(1):15-9. doi: 10.3816/CBC.2011.n.003.

Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.

Expert Rev Anticancer Ther. 2015 Jan;15(1):17-26. doi: 10.1586/14737140.2015.992418. Epub 2014 Dec 12.

引用本文的文献

HER2; p53 Co-mutated Cancers Show Increased Histone Acetylation and are Sensitive to Neratinib plus Trastuzumab Deruxtecan.

bioRxiv. 2025 Jul 10:2025.07.06.663368. doi: 10.1101/2025.07.06.663368.

Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer-A Literature Review.

Cancers (Basel). 2023 Aug 30;15(17):4336. doi: 10.3390/cancers15174336.

Recent Advances in the Role of Autophagy in Endocrine-Dependent Tumors.

Endocr Rev. 2023 Jul 11;44(4):629-646. doi: 10.1210/endrev/bnad001.

Revisiting characteristics of oncogenic extrachromosomal DNA as mobile enhancers on neuroblastoma and glioma cancers.

Cancer Cell Int. 2022 May 25;22(1):200. doi: 10.1186/s12935-022-02617-8.

Lysine Acetylation/Deacetylation Modification of Immune-Related Molecules in Cancer Immunotherapy.

Front Immunol. 2022 May 2;13:865975. doi: 10.3389/fimmu.2022.865975. eCollection 2022.

Remodeling the Tumor Myeloid Landscape to Enhance Antitumor Antibody Immunotherapies.

Cancers (Basel). 2021 Sep 29;13(19):4904. doi: 10.3390/cancers13194904.

Laser Capture Proteomics: spatial tissue molecular profiling from the bench to personalized medicine.

Expert Rev Proteomics. 2021 Oct;18(10):845-861. doi: 10.1080/14789450.2021.1984886. Epub 2021 Dec 14.

Novel insights into extrachromosomal DNA: redefining the onco-drivers of tumor progression.

J Exp Clin Cancer Res. 2020 Oct 12;39(1):215. doi: 10.1186/s13046-020-01726-4.

Reprogramming the Constant Region of Immunoglobulin G Subclasses for Enhanced Therapeutic Potency against Cancer.

Biomolecules. 2020 Mar 1;10(3):382. doi: 10.3390/biom10030382.

Prevalence and role of HER2 mutations in cancer.

Pharmacol Ther. 2019 Jul;199:188-196. doi: 10.1016/j.pharmthera.2019.03.010. Epub 2019 Apr 2.